Esranur Aydın, Clinical Cancer Molecular Biologist at Medicana Sağlık Grubu, shared a post on LinkedIn:
“I had the privilege of presenting our work at the American Society of Clinical Oncology (ASCO) Annual Meeting, representing a project that is very close to my heart!
Our team brought a specific focus to Chicago this year. We spent the day discussing our latest work on BRAF non-V600E and MAP2K1 alterations —rare mutations that often leave clinicians with more questions than answers when standard protocols fail.
Looking at data from 4,774 patients in the global WAYFIND-R registry, our study highlights how analyzing the specific functional biology of these alterations allows us to design smarter, personalized combinations. Seeing sustained responses and even molecular clearance with MEK inhibitor + immunotherapy strategies shows we’re on the right track.
The future of precision oncology isn’t just about finding mutations; it’s about understanding their functional classes to make better clinical choices.
For those interested, the abstract details and poster are available.
Brilliant minds, intense discussions, and a lot of shared passion for precision medicine. Thank you to everyone who made this collaboration happen!”
Other articles featuring Esranur Aydın on OncoDaily.